業績公告
即時報告
8-K
2026-05-14
Cabaletta Bio 提交8-K公布首季业绩 惟未披露具体财务数字
AI 繁中摘要
Cabaletta Bio, Inc.（納斯達克代碼：CABA）於2026年5月14日提交8-K申報文件，公佈截至2026年3月31日第一季度（2026財年第一季）的財務業績。新聞稿作為附件99.1隨本報告一併提交，惟未被視為「已存檔」於《交易法》第18條項下。
本次8-K僅屬提供性質，未披露具體營收、研發開支或現金結餘等財務數字。投資者應直接查閱新聞稿全文，以了解季度虧損、每股盈餘、臨床進展及管理層對未來營運的展望。
📌 對投資者的潛在影響：業績公佈後股價或出現短期波動，尤其是若新聞稿中載有超出市場預期的臨床試驗數據或資金消耗率變動。建議仔細閱讀新聞稿中的關鍵指標及管理層評論。
展開英文正文
8-K 0001759138false00017591382026-05-142026-05-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 CABALETTA BIO, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-39103 82-1685768 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 2929 Arch Street Suite 600 Philadelphia, Pennsylvania 19104 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (267) 759-3100 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.00001 per share CABA The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 2.02 Results of Operations and Financial Condition. On May 14, 2026, Cabaletta Bio, Inc. (the “Company”) announced its financial results for the first quarter ended March 31, 2026. A copy of the press release is being furnished as Exhibit 99.1 to this Report on Form 8-K. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release issued by the registrant on May 14, 2026, furnished herewith. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document). SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CABALETTA BIO, INC. Date: May 14, 2026 By: /s/ Steven Nichtberger Steven Nichtberger Chief Executive Officer and President (Principal Executive Officer)